NeVa Retrospective Comparative SR Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-15

Study Completion Date

2026-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare safety and effectiveness of NeVa Stent Retriever (SR) to Control SR in the treatment of stroke caused by large vessel occlusion. The main questions it aims to answer are:

How do recanalization rates for NeVa SR compare with those of the Control SR? How does NeVa SR safety compare with Control SR safety?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Vesalio NeVa Stent Retriever Registry Study for Treatment of Large Vessel Occlusion Strokes

NCT03926988

Acute Ischemic Stroke

UNKNOWN NA

FIrst-Pass Reperfusion With the NeVa Stent-Retriever Trial

NCT04072367

Acute Ischemic Stroke

WITHDRAWN NA

NeVa ONE Registry Study

NCT04562194

Acute Ischemic Stroke

RECRUITING NA

The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR Study

NCT04514562

Acute Ischemic Stroke

UNKNOWN NA

The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes

NCT03927001

Acute Ischemic Stroke

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

NITRO is a multicenter, retrospective, comparative, non-inferiority, cohort study designed to compare NeVa SR with Control SR for safety and effectiveness when removing thrombus in subjects presenting with acute ischemic stroke (AIS) due to large vessel occlusion (LVO). The objective of the NeVa International, Multi-center, Retrospective Comparative stent retriever (SR) study (NITRO) study is to compare safety and effectiveness of the NeVa SR to commonly used SR with CE-mark, and US FDA clearance, to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion. NITRO aims to collect data describing real-world clinical practices when using SRs according to their indicated use within the indicated population. As such, the eligibility criteria define patients who are diagnosed with AIS and are indicated for endovascular MT aligning to the target population for the proposed device. The present study will include data from subjects treated with either NeVa SR or one of the Control SR. Control SR will include any SR commonly used in thrombectomy trials as first-line strategies and which represent CE-mark, and US FDA cleared stent retrievers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients experiencing acute ischemic stroke due to large vessel occlusion

According to Guidelines AIS patients due to LVO should receive mechanical thrombectomy (with a stent retriever) under certain conditions.

Mechanical thrombectomy

Intervention Type PROCEDURE

Mechanical thrombectomy with stent retriever

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mechanical thrombectomy

Mechanical thrombectomy with stent retriever

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treatment during the enrollment period
* Age ≥18
* Baseline modified Thrombolysis in Cerebral Infarction (mTICI) score ≤ 1
* Pre-stroke modified Rankin score (mRS) of 0 or 1
* Internal Carotid Artery (ICA), Middle Cerebral Artery (first segment M1/ second segment M2), basilar artery or vertebral artery occlusion
* National Institutes of Health Stroke Scale (NIHSS) score ≥ 8 and ≤ 25
* Thrombectomy procedure initiated within 8h of Time Last Known Well (TLKW)
* Intravenous Tissue Plasminogen Activator (IV-tPA) failed, given within 3h of TLKW, or ineligibility for thrombolytic drug